Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale
Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various mutations in the acid alpha-glucosidase gene lead to toxic lysosomal and extra-lysosomal glycogen accumulation in all organs due to ineffective g...
Uloženo v:
| Vydáno v: | Journal of neurology Ročník 266; číslo 8; s. 2010 - 2017 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.08.2019
Springer Nature B.V |
| Témata: | |
| ISSN: | 0340-5354, 1432-1459, 1432-1459 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various mutations in the acid alpha-glucosidase gene lead to toxic lysosomal and extra-lysosomal glycogen accumulation in all organs due to ineffective glycogen clearance by the encoded enzyme. Only one randomized trial demonstrated beneficial effects of respiratory function and meters walked in the 6-min walking test with enzyme replacement therapy (ERT). These results were confirmed in several retrospective and prospective observations and in meta-analyses. Due to a potential lifelong therapy, moderate efficacy and high treatment costs time of ERT initiation and cessation is an ongoing matter of debate. So far, several national and international recommendations have been published with different criteria concerning diagnosis, initiation and cessation of ERT in LOPD. We therefore formally analysed recent published recommendations and consensus statements of LOPD using diagnostic nodes (DODES) as a special software tool. With DODES, an objective analysis becomes possible if the content of the recommendations is represented as algorithms using cross-compatible elements. This analysis formally disclosed both, areas of great heterogeneity and concordance for the diagnosis and management of LOPD and paved the way for a Pompe disease burden scale focussing on ERT initiation. According to this investigation further clinical research should concentrate on ERT in pre-symptomatic and severely affected LOPD patients and on cessation criteria for ERT as these issues are areas of international uncertainty and discordance. |
|---|---|
| AbstractList | Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various mutations in the acid alpha-glucosidase gene lead to toxic lysosomal and extra-lysosomal glycogen accumulation in all organs due to ineffective glycogen clearance by the encoded enzyme. Only one randomized trial demonstrated beneficial effects of respiratory function and meters walked in the 6-min walking test with enzyme replacement therapy (ERT). These results were confirmed in several retrospective and prospective observations and in meta-analyses. Due to a potential lifelong therapy, moderate efficacy and high treatment costs time of ERT initiation and cessation is an ongoing matter of debate. So far, several national and international recommendations have been published with different criteria concerning diagnosis, initiation and cessation of ERT in LOPD. We therefore formally analysed recent published recommendations and consensus statements of LOPD using diagnostic nodes (DODES) as a special software tool. With DODES, an objective analysis becomes possible if the content of the recommendations is represented as algorithms using cross-compatible elements. This analysis formally disclosed both, areas of great heterogeneity and concordance for the diagnosis and management of LOPD and paved the way for a Pompe disease burden scale focussing on ERT initiation. According to this investigation further clinical research should concentrate on ERT in pre-symptomatic and severely affected LOPD patients and on cessation criteria for ERT as these issues are areas of international uncertainty and discordance. Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various mutations in the acid alpha-glucosidase gene lead to toxic lysosomal and extra-lysosomal glycogen accumulation in all organs due to ineffective glycogen clearance by the encoded enzyme. Only one randomized trial demonstrated beneficial effects of respiratory function and meters walked in the 6-min walking test with enzyme replacement therapy (ERT). These results were confirmed in several retrospective and prospective observations and in meta-analyses. Due to a potential lifelong therapy, moderate efficacy and high treatment costs time of ERT initiation and cessation is an ongoing matter of debate. So far, several national and international recommendations have been published with different criteria concerning diagnosis, initiation and cessation of ERT in LOPD. We therefore formally analysed recent published recommendations and consensus statements of LOPD using diagnostic nodes (DODES) as a special software tool. With DODES, an objective analysis becomes possible if the content of the recommendations is represented as algorithms using cross-compatible elements. This analysis formally disclosed both, areas of great heterogeneity and concordance for the diagnosis and management of LOPD and paved the way for a Pompe disease burden scale focussing on ERT initiation. According to this investigation further clinical research should concentrate on ERT in pre-symptomatic and severely affected LOPD patients and on cessation criteria for ERT as these issues are areas of international uncertainty and discordance.Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various mutations in the acid alpha-glucosidase gene lead to toxic lysosomal and extra-lysosomal glycogen accumulation in all organs due to ineffective glycogen clearance by the encoded enzyme. Only one randomized trial demonstrated beneficial effects of respiratory function and meters walked in the 6-min walking test with enzyme replacement therapy (ERT). These results were confirmed in several retrospective and prospective observations and in meta-analyses. Due to a potential lifelong therapy, moderate efficacy and high treatment costs time of ERT initiation and cessation is an ongoing matter of debate. So far, several national and international recommendations have been published with different criteria concerning diagnosis, initiation and cessation of ERT in LOPD. We therefore formally analysed recent published recommendations and consensus statements of LOPD using diagnostic nodes (DODES) as a special software tool. With DODES, an objective analysis becomes possible if the content of the recommendations is represented as algorithms using cross-compatible elements. This analysis formally disclosed both, areas of great heterogeneity and concordance for the diagnosis and management of LOPD and paved the way for a Pompe disease burden scale focussing on ERT initiation. According to this investigation further clinical research should concentrate on ERT in pre-symptomatic and severely affected LOPD patients and on cessation criteria for ERT as these issues are areas of international uncertainty and discordance. |
| Author | Rösler, Kai Michael Schoser, Benedikt Putora, Paul Martin Leupold, Daniela Hundsberger, Thomas |
| Author_xml | – sequence: 1 givenname: Thomas orcidid: 0000-0002-4419-2767 surname: Hundsberger fullname: Hundsberger, Thomas email: thomas.hundsberger@kssg.ch organization: Department of Neurology, Cantonal Hospital St. Gallen – sequence: 2 givenname: Benedikt surname: Schoser fullname: Schoser, Benedikt organization: Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University – sequence: 3 givenname: Daniela surname: Leupold fullname: Leupold, Daniela organization: Department of Neurology, Cantonal Hospital St. Gallen, Department of Neurology, Royal Melbourne Hospital – sequence: 4 givenname: Kai Michael surname: Rösler fullname: Rösler, Kai Michael organization: Department of Neurology, University of Bern, Neurozentrum Basel – sequence: 5 givenname: Paul Martin surname: Putora fullname: Putora, Paul Martin organization: Department of Radiation Oncology, Cantonal Hospital, Department of Radiation Oncology, University of Bern |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31104135$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtuFDEQhi0URCaBC7BAltiwaSi_-rFEIyCRIsEC1pZjVw-Ouu3BdiOx4xAcgLNxEtyZjBBZZGWV_H2_SvWfkZMQAxLynMFrBtC9yQCSqQbY0MAgOtHwR2TDpOANk2o4IRsQEhollDwlZznfAEBfP56QU8FYVYXakN_bOO9N8jkGGkea0GIodO-_x2KmdYzzjMGZ4mPIdIyJlq9InTe7ELPP1ARHS0JT5tWrCZMp2FQWC_1Uo1c2o8lIl-zD7mgWb2mIDvOfn7_WwP_R6yU5DDRbM-FT8ng0U8Znd-85-fL-3eftRXP18cPl9u1VY6VkpZFcSifsAKNse9GPrbPIlQLXqU4BM8opwd0gse0ksE6gY2JAy6wxAvpxEOfk1SF3n-K3BXPRs88Wp8kEjEvWnAsOHet5V9GX99CbuKRQt6sUbwcGbccr9eKOWq5ndHqf_GzSD328fQX6A2BTzDnhqK0vt4cuyfhJM9BrzfpQs64169ua9ZrN76nH9AclcZByhcMO07-1H7D-AsE1vHE |
| CitedBy_id | crossref_primary_10_1111_ene_16383 crossref_primary_10_1183_23120541_00159_2019 crossref_primary_10_1007_s00259_019_04557_4 crossref_primary_10_3390_ijns6020031 crossref_primary_10_1186_s12884_022_04584_4 crossref_primary_10_1016_j_nmd_2021_02_013 |
| Cites_doi | 10.1007/s13760-019-01097-4 10.1186/s12883-017-0983-2 10.1007/s13311-018-0655-y 10.1186/s13023-017-0741-y 10.1016/j.ymgme.2012.09.015 10.1016/j.ymgme.2011.09.012 10.1111/ene.13285 10.1007/s10545-015-9889-6 10.1159/000492272 10.1590/0004-282X20150194 10.7196/SAMJ.7386 10.1111/dmcn.13762 10.1007/s00415-013-6980-5 10.1002/mus.22329 10.1007/s00415-012-6636-x 10.1016/j.nmd.2018.08.002 10.1203/PDR.0b013e3181b24e94 10.1007/s11060-015-1957-0 10.1212/WNL.0000000000002758 10.1186/1750-1172-8-49 10.1016/j.ymgme.2013.05.021 10.2196/jmir.2452 10.1007/s10545-018-0198-8 10.1007/s10545-012-9451-8 10.1186/s12894-018-0332-9 10.1111/ene.13730 10.1007/s00415-018-9065-7 10.1016/j.nmd.2015.04.006 10.1016/j.ymgme.2011.06.012 10.1007/s00415-014-7402-z 10.1016/S0140-6736(08)61555-X 10.1007/s00415-016-8219-8 10.1186/s12883-015-0412-3 10.1111/dmcn.13740 10.1017/cjn.2016.37 10.1212/WNL.0000000000004711 10.5166/jroi-2-1-6 10.1007/s00415-015-7664-0 10.1007/s00415-017-8686-6 10.1056/NEJMoa0909859 10.1212/WNL.0b013e3182553c11 10.1186/s12874-017-0400-y 10.1186/s13014-014-0270-y 10.1007/s00415-009-5275-3 10.1097/01.gim.0000218152.87434.f3 10.1016/j.ymgme.2013.03.016 10.1038/gim.2016.70 10.1136/jnnp-2014-310164 10.1002/mus.24653 10.1111/ene.13835 10.1200/CCI.18.00017 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag GmbH Germany, part of Springer Nature 2019 Journal of Neurology is a copyright of Springer, (2019). All Rights Reserved. |
| Copyright_xml | – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2019 – notice: Journal of Neurology is a copyright of Springer, (2019). All Rights Reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s00415-019-09373-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest ProQuest Databases ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1432-1459 |
| EndPage | 2017 |
| ExternalDocumentID | 31104135 10_1007_s00415_019_09373_2 |
| Genre | Journal Article Comparative Study Review |
| GroupedDBID | --- -53 -5E -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 203 29L 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 40D 40E 53G 5RE 5VS 67Z 6NX 78A 7X7 88E 8AO 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABUWG ABUWZ ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACZOJ ADBBV ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN B-. BA0 BENPR BGNMA BPHCQ BSONS BVXVI CCPQU CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FNLPD FRRFC FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M4Y MA- N9A NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNS ROL RPX RRX RSV S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z81 Z82 Z83 Z87 Z8O Z8U Z8V Z8W Z91 Z92 ZMTXR ZOVNA ~EX ~KM -Y2 .55 .GJ 2.D 28- 2P1 2VQ 3SX 5QI AANXM AAPKM AARHV AAYTO AAYXX ABBRH ABDBE ABFSG ABQSL ABRTQ ABULA ACBXY ACSTC ACUDM ADHKG AEBTG AEFIE AEKMD AEZWR AFDYV AFDZB AFEXP AFFHD AFFNX AFHIU AFOHR AGGDS AGQPQ AHPBZ AHWEU AIXLP AJBLW ATHPR AYFIA BBWZM BDATZ CAG CITATION COF EN4 FINBP FSGXE GRRUI H13 KOW N2Q NDZJH O9- OVD PHGZM PHGZT PJZUB PPXIY RNI RZK S1Z S26 S28 SCLPG SDE T16 TEORI WK6 X7M ZGI ZXP 3V. CGR CUY CVF ECM EIF NPM RIG 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c441t-4244d3c90f46838f6dce2550d757501a5d532d94e6740173ed139ec1caa308f93 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000476506500021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-5354 1432-1459 |
| IngestDate | Wed Oct 01 14:00:53 EDT 2025 Tue Nov 04 22:28:27 EST 2025 Wed Feb 19 02:31:54 EST 2025 Sat Nov 29 02:48:30 EST 2025 Tue Nov 18 22:14:15 EST 2025 Fri Feb 21 02:43:00 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Pompe disease ERT initiation Enzyme replacement therapy Diagnostic nodes ERT cessation Guidelines |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c441t-4244d3c90f46838f6dce2550d757501a5d532d94e6740173ed139ec1caa308f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-4419-2767 |
| PMID | 31104135 |
| PQID | 2226910672 |
| PQPubID | 47196 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2232071827 proquest_journals_2226910672 pubmed_primary_31104135 crossref_citationtrail_10_1007_s00415_019_09373_2 crossref_primary_10_1007_s00415_019_09373_2 springer_journals_10_1007_s00415_019_09373_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-08-01 |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Journal of neurology |
| PublicationTitleAbbrev | J Neurol |
| PublicationTitleAlternate | J Neurol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Llerena Junior, Nascimento, Oliveira (CR23) 2016; 74 Kishnani, Corzo, Leslie (CR4) 2009; 66 Scheidegger, Leupold, Sauter (CR46) 2018; 265 Toscano, Schoser (CR16) 2013; 260 Kohler, Puertollano, Raben (CR42) 2018; 15 Kishnani, Steiner, Bali (CR3) 2006; 8 Putora, Oldenburg (CR29) 2013; 15 De Vries, Kuperus, Hoogeveen-Westerveld (CR35) 2017; 19 Cupler, Berger, Leshner (CR22) 2012; 45 Tarnopolsky, Katzberg, Petrof (CR20) 2016; 43 Hundsberger, Rösler, Findling (CR45) 2014; 261 Güngör, Schober, Kruijshaar (CR12) 2013; 109 Bhengu, Davidson, du Toit (CR24) 2014; 104 van der Ploeg, Clemens, Corzo (CR14) 2010; 362 Musumeci, Marino, Granata (CR50) 2018; 26 Musumeci, la Marca, Spada (CR17) 2016; 87 Putora, Panje, Papachristofilou (CR28) 2014; 9 van der Ploeg, Kruijshaar, Toscano (CR25) 2017; 24 Güngör, Kruijshaar, Plug (CR9) 2013; 8 van Houtte, De Bleecker (CR36) 2019; 119 Schoser, Laforêt, Kruijshaar (CR26) 2015; 25 Chien, Lee, Hwu, Fang (CR48) 2018; 25 Güngör, Kruijshaar, Plug (CR10) 2016; 39 Strothotte, Strigl-Pill, Grunert (CR39) 2010; 257 Echaniz-Laguna, Carlier, Laloui (CR34) 2015; 51 Zumstein, Betschart, Abt (CR32) 2018; 18 Güngör, De Vries, Brusse (CR11) 2013; 109 van der Ploeg, Reuser (CR1) 2008; 372 Montagnese, Barca, Musumeci (CR8) 2015; 262 Panje, Glatzer, Sirén (CR41) 2018; 2 Glatzer, Panje, Sirén (CR49) 2018 Panje, Glatzer, von Rappard (CR30) 2017; 17 Kuperus, Kruijshaar, Wens (CR15) 2017; 89 de Vries, Brugma, Özkan (CR38) 2011; 104 Lukacs, Cobos, Wenninger (CR33) 2016; 87 Van Der Meijden, Kruijshaar, Rizopoulos (CR44) 2018; 13 Ebbink, Poelman, Aarsen (CR5) 2018; 60 Al Jasmi, Al Jumah, Alqarni (CR21) 2015; 15 Van der Ploeg, Barohn, Carlson (CR47) 2012; 107 Löscher, Huemer, Stulnig (CR2) 2018; 265 Schoser, Bilder, Dimmock (CR13) 2017; 17 van der Beek, van Capelle, van der Velden-van Etten (CR18) 2011; 104 Schoser (CR51) 2018; 60 Hundsberger, Hottinger, Roelcke (CR31) 2016; 126 Schoser, Stewart, Kanters (CR40) 2017; 264 Ebbink, Aarsen, Van Gelder (CR6) 2012; 78 Hundsberger, Rohrbach, Kern, Rösler (CR19) 2013; 260 Milverton, Newton, Merlin (CR7) 2018; 42 Regnery, Kornblum, Hanisch (CR43) 2012; 35 Oliveira Santos, Evangelista, Conceição (CR37) 2018; 28 Putora, Blattner (CR27) 2010; 2 V Zumstein (9373_CR32) 2018; 18 C Regnery (9373_CR43) 2012; 35 JM De Vries (9373_CR35) 2017; 19 E Kuperus (9373_CR15) 2017; 89 JC Van Der Meijden (9373_CR44) 2018; 13 AT Van der Ploeg (9373_CR47) 2012; 107 S Strothotte (9373_CR39) 2010; 257 B Schoser (9373_CR13) 2017; 17 B Schoser (9373_CR26) 2015; 25 D Güngör (9373_CR9) 2013; 8 P Putora (9373_CR27) 2010; 2 M Oliveira Santos (9373_CR37) 2018; 28 O Musumeci (9373_CR17) 2016; 87 Y-H Chien (9373_CR48) 2018; 25 AT van der Ploeg (9373_CR1) 2008; 372 F Montagnese (9373_CR8) 2015; 262 L Kohler (9373_CR42) 2018; 15 PM Putora (9373_CR28) 2014; 9 WN Löscher (9373_CR2) 2018; 265 B Schoser (9373_CR51) 2018; 60 PM Putora (9373_CR29) 2013; 15 A Echaniz-Laguna (9373_CR34) 2015; 51 J Milverton (9373_CR7) 2018; 42 AT van der Ploeg (9373_CR25) 2017; 24 J van Houtte (9373_CR36) 2019; 119 PS Kishnani (9373_CR3) 2006; 8 NAME van der Beek (9373_CR18) 2011; 104 M Tarnopolsky (9373_CR20) 2016; 43 T Hundsberger (9373_CR31) 2016; 126 M Glatzer (9373_CR49) 2018 CM Panje (9373_CR41) 2018; 2 BJ Ebbink (9373_CR5) 2018; 60 B Schoser (9373_CR40) 2017; 264 EJ Cupler (9373_CR22) 2012; 45 AT van der Ploeg (9373_CR14) 2010; 362 A Toscano (9373_CR16) 2013; 260 D Güngör (9373_CR12) 2013; 109 T Hundsberger (9373_CR19) 2013; 260 D Güngör (9373_CR10) 2016; 39 JC Llerena Junior (9373_CR23) 2016; 74 CM Panje (9373_CR30) 2017; 17 PS Kishnani (9373_CR4) 2009; 66 F Al Jasmi (9373_CR21) 2015; 15 BJ Ebbink (9373_CR6) 2012; 78 D Güngör (9373_CR11) 2013; 109 T Hundsberger (9373_CR45) 2014; 261 O Musumeci (9373_CR50) 2018; 26 Z Lukacs (9373_CR33) 2016; 87 O Scheidegger (9373_CR46) 2018; 265 L Bhengu (9373_CR24) 2014; 104 JM de Vries (9373_CR38) 2011; 104 |
| References_xml | – volume: 119 start-page: 1 year: 2019 end-page: 3 ident: CR36 article-title: Two successfully completed pregnancies in adult onset Pompe disease, under continued treatment with alglucosidase alfa publication-title: Acta Neurol Belg doi: 10.1007/s13760-019-01097-4 – volume: 17 start-page: 202 year: 2017 ident: CR13 article-title: The humanistic burden of Pompe disease: are there still unmet needs? A systematic review publication-title: BMC Neurol doi: 10.1186/s12883-017-0983-2 – volume: 15 start-page: 928 year: 2018 end-page: 942 ident: CR42 article-title: Pompe disease: from basic science to therapy publication-title: Neurotherapeutics doi: 10.1007/s13311-018-0655-y – volume: 13 start-page: 1 year: 2018 end-page: 6 ident: CR44 article-title: Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-017-0741-y – volume: 107 start-page: 456 year: 2012 end-page: 61 ident: CR47 article-title: Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2012.09.015 – volume: 104 start-page: 552 year: 2011 end-page: 555 ident: CR38 article-title: First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2011.09.012 – volume: 24 start-page: 768 year: 2017 end-page: e31 ident: CR25 article-title: European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience publication-title: Eur J Neurol doi: 10.1111/ene.13285 – volume: 39 start-page: 253 year: 2016 end-page: 260 ident: CR10 article-title: Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up publication-title: J Inherit Metab Dis doi: 10.1007/s10545-015-9889-6 – year: 2018 ident: CR49 article-title: Decision making criteria in oncology publication-title: Oncology doi: 10.1159/000492272 – volume: 74 start-page: 166 year: 2016 end-page: 176 ident: CR23 article-title: Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease publication-title: Arq Neuropsiquiatr doi: 10.1590/0004-282X20150194 – volume: 104 start-page: 273 year: 2014 end-page: 274 ident: CR24 article-title: Diagnosis and management of Pompe disease publication-title: S Afr Med J doi: 10.7196/SAMJ.7386 – volume: 60 start-page: 536 year: 2018 end-page: 536 ident: CR51 article-title: Novel Pompe disease phenotype: a treatment-related modified phenotype neglecting the brain publication-title: Dev Med Child Neurol doi: 10.1111/dmcn.13762 – volume: 260 start-page: 2279 year: 2013 end-page: 2285 ident: CR19 article-title: Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease publication-title: J Neurol doi: 10.1007/s00415-013-6980-5 – volume: 45 start-page: 319 year: 2012 end-page: 333 ident: CR22 article-title: Consensus treatment recommendations for late-onset Pompe disease publication-title: Muscle Nerve doi: 10.1002/mus.22329 – volume: 260 start-page: 951 year: 2013 end-page: 959 ident: CR16 article-title: Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review publication-title: J Neurol doi: 10.1007/s00415-012-6636-x – volume: 28 start-page: 965 year: 2018 end-page: 968 ident: CR37 article-title: Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy publication-title: Neuromuscul Disord doi: 10.1016/j.nmd.2018.08.002 – volume: 66 start-page: 329 year: 2009 end-page: 335 ident: CR4 article-title: Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease publication-title: Pediatr Res doi: 10.1203/PDR.0b013e3181b24e94 – volume: 126 start-page: 175 year: 2016 end-page: 183 ident: CR31 article-title: Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes publication-title: J Neurooncol doi: 10.1007/s11060-015-1957-0 – volume: 87 start-page: 295 year: 2016 end-page: 298 ident: CR33 article-title: Prevalence of Pompe disease in 3076 patients with hyperCKemia and limb-girdle muscular weakness publication-title: Neurology doi: 10.1212/WNL.0000000000002758 – volume: 8 start-page: 49 year: 2013 ident: CR9 article-title: Impact of enzyme replacement therapy on survival in adults with Pompe disease: Results from a prospective international observational study publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-8-49 – volume: 109 start-page: 371 year: 2013 end-page: 376 ident: CR12 article-title: Pain in adult patients with Pompe disease: a cross-sectional survey publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.05.021 – volume: 15 start-page: e207 year: 2013 ident: CR29 article-title: Swarm-based medicine publication-title: J Med Internet Res doi: 10.2196/jmir.2452 – volume: 42 start-page: 1 year: 2018 end-page: 8 ident: CR7 article-title: The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review publication-title: J Inherit Metab Dis doi: 10.1007/s10545-018-0198-8 – volume: 35 start-page: 837 year: 2012 end-page: 45 ident: CR43 article-title: 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy publication-title: J Inherit Metab Dis doi: 10.1007/s10545-012-9451-8 – volume: 18 start-page: 25 year: 2018 ident: CR32 article-title: Surgical management of urolithiasis—a systematic analysis of available guidelines publication-title: BMC Urol doi: 10.1186/s12894-018-0332-9 – volume: 25 start-page: e111 year: 2018 end-page: e111 ident: CR48 article-title: Disease progression in a pre-symptomatically treated patient with juvenile-onset Pompe disease—need for an earlier treatment? publication-title: Eur J Neurol doi: 10.1111/ene.13730 – volume: 265 start-page: 2783 year: 2018 end-page: 2788 ident: CR46 article-title: 36-months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry publication-title: J Neurol doi: 10.1007/s00415-018-9065-7 – volume: 25 start-page: 674 year: 2015 end-page: 678 ident: CR26 article-title: 208th ENMC International Workshop: formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26–28 September 2014 publication-title: Neuromuscul Disord doi: 10.1016/j.nmd.2015.04.006 – volume: 104 start-page: 129 year: 2011 end-page: 136 ident: CR18 article-title: Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2011.06.012 – volume: 261 start-page: 1684 year: 2014 end-page: 90 ident: CR45 article-title: Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis publication-title: J Neurol doi: 10.1007/s00415-014-7402-z – volume: 372 start-page: 1342 year: 2008 end-page: 1353 ident: CR1 article-title: Pompe’s disease publication-title: Lancet doi: 10.1016/S0140-6736(08)61555-X – volume: 264 start-page: 621 year: 2017 end-page: 630 ident: CR40 article-title: Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis publication-title: J Neurol doi: 10.1007/s00415-016-8219-8 – volume: 15 start-page: 205 year: 2015 ident: CR21 article-title: Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group publication-title: BMC Neurol doi: 10.1186/s12883-015-0412-3 – volume: 60 start-page: 579 year: 2018 end-page: 586 ident: CR5 article-title: Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain publication-title: Dev Med Child Neurol doi: 10.1111/dmcn.13740 – volume: 43 start-page: 1 year: 2016 end-page: 14 ident: CR20 article-title: Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel publication-title: Can J Neurol Sci doi: 10.1017/cjn.2016.37 – volume: 89 start-page: 2365 year: 2017 end-page: 2373 ident: CR15 article-title: Long-term benefit of enzyme replacement therapy in Pompe disease publication-title: Neurology doi: 10.1212/WNL.0000000000004711 – volume: 2 start-page: 1 year: 2010 end-page: 8 ident: CR27 article-title: Dodes (diagnostic nodes) for guideline manipulation publication-title: J Radiat Onc Inform doi: 10.5166/jroi-2-1-6 – volume: 262 start-page: 968 year: 2015 end-page: 978 ident: CR8 article-title: Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment publication-title: J Neurol doi: 10.1007/s00415-015-7664-0 – volume: 265 start-page: 159 year: 2018 end-page: 164 ident: CR2 article-title: Pompe disease in Austria: clinical, genetic and epidemiological aspects publication-title: J Neurol doi: 10.1007/s00415-017-8686-6 – volume: 362 start-page: 1396 year: 2010 end-page: 1406 ident: CR14 article-title: A randomized study of alglucosidase alfa in late-onset Pompe’s disease publication-title: N Engl J Med doi: 10.1056/NEJMoa0909859 – volume: 78 start-page: 1512 year: 2012 end-page: 1518 ident: CR6 article-title: Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy publication-title: Neurology doi: 10.1212/WNL.0b013e3182553c11 – volume: 17 start-page: 123 year: 2017 ident: CR30 article-title: Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis publication-title: BMC Med Res Methodol doi: 10.1186/s12874-017-0400-y – volume: 9 start-page: 270 year: 2014 ident: CR28 article-title: Objective consensus from decision trees publication-title: Radiat Oncol doi: 10.1186/s13014-014-0270-y – volume: 257 start-page: 91 year: 2010 end-page: 97 ident: CR39 article-title: Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial publication-title: J Neurol doi: 10.1007/s00415-009-5275-3 – volume: 8 start-page: 267 year: 2006 end-page: 288 ident: CR3 article-title: Pompe disease diagnosis and management guideline publication-title: Genet Med doi: 10.1097/01.gim.0000218152.87434.f3 – volume: 109 start-page: 174 year: 2013 end-page: 178 ident: CR11 article-title: Enzyme replacement therapy and fatigue in adults with Pompe disease publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.03.016 – volume: 19 start-page: 90 year: 2017 end-page: 97 ident: CR35 article-title: Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy publication-title: Genet Med doi: 10.1038/gim.2016.70 – volume: 87 start-page: 5 year: 2016 end-page: 11 ident: CR17 article-title: LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2014-310164 – volume: 51 start-page: 884 year: 2015 end-page: 889 ident: CR34 article-title: Should patients with asymptomatic pompe disease be treated? A nationwide study in france publication-title: Muscle Nerve doi: 10.1002/mus.24653 – volume: 26 start-page: 442 year: 2018 end-page: 451 ident: CR50 article-title: Central nervous system involvement in late onset Pompe disease (LOPD): clues from neuroimaging and neuropsychological analysis publication-title: Eur J Neurol doi: 10.1111/ene.13835 – volume: 2 start-page: 1 year: 2018 end-page: 10 ident: CR41 article-title: Treatment Options in Oncology publication-title: JCO Clin cancer informatics doi: 10.1200/CCI.18.00017 – volume: 372 start-page: 1342 year: 2008 ident: 9373_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(08)61555-X – volume: 87 start-page: 295 year: 2016 ident: 9373_CR33 publication-title: Neurology doi: 10.1212/WNL.0000000000002758 – volume: 60 start-page: 579 year: 2018 ident: 9373_CR5 publication-title: Dev Med Child Neurol doi: 10.1111/dmcn.13740 – volume: 25 start-page: 674 year: 2015 ident: 9373_CR26 publication-title: Neuromuscul Disord doi: 10.1016/j.nmd.2015.04.006 – volume: 9 start-page: 270 year: 2014 ident: 9373_CR28 publication-title: Radiat Oncol doi: 10.1186/s13014-014-0270-y – volume: 25 start-page: e111 year: 2018 ident: 9373_CR48 publication-title: Eur J Neurol doi: 10.1111/ene.13730 – volume: 42 start-page: 1 year: 2018 ident: 9373_CR7 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-018-0198-8 – volume: 2 start-page: 1 year: 2018 ident: 9373_CR41 publication-title: JCO Clin cancer informatics doi: 10.1200/CCI.18.00017 – volume: 8 start-page: 49 year: 2013 ident: 9373_CR9 publication-title: Orphanet J Rare Dis doi: 10.1186/1750-1172-8-49 – volume: 45 start-page: 319 year: 2012 ident: 9373_CR22 publication-title: Muscle Nerve doi: 10.1002/mus.22329 – volume: 8 start-page: 267 year: 2006 ident: 9373_CR3 publication-title: Genet Med doi: 10.1097/01.gim.0000218152.87434.f3 – volume: 17 start-page: 123 year: 2017 ident: 9373_CR30 publication-title: BMC Med Res Methodol doi: 10.1186/s12874-017-0400-y – volume: 15 start-page: 928 year: 2018 ident: 9373_CR42 publication-title: Neurotherapeutics doi: 10.1007/s13311-018-0655-y – volume: 66 start-page: 329 year: 2009 ident: 9373_CR4 publication-title: Pediatr Res doi: 10.1203/PDR.0b013e3181b24e94 – volume: 107 start-page: 456 year: 2012 ident: 9373_CR47 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2012.09.015 – volume: 78 start-page: 1512 year: 2012 ident: 9373_CR6 publication-title: Neurology doi: 10.1212/WNL.0b013e3182553c11 – volume: 362 start-page: 1396 year: 2010 ident: 9373_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa0909859 – volume: 17 start-page: 202 year: 2017 ident: 9373_CR13 publication-title: BMC Neurol doi: 10.1186/s12883-017-0983-2 – volume: 109 start-page: 174 year: 2013 ident: 9373_CR11 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.03.016 – volume: 109 start-page: 371 year: 2013 ident: 9373_CR12 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2013.05.021 – volume: 257 start-page: 91 year: 2010 ident: 9373_CR39 publication-title: J Neurol doi: 10.1007/s00415-009-5275-3 – volume: 60 start-page: 536 year: 2018 ident: 9373_CR51 publication-title: Dev Med Child Neurol doi: 10.1111/dmcn.13762 – volume: 19 start-page: 90 year: 2017 ident: 9373_CR35 publication-title: Genet Med doi: 10.1038/gim.2016.70 – volume: 89 start-page: 2365 year: 2017 ident: 9373_CR15 publication-title: Neurology doi: 10.1212/WNL.0000000000004711 – volume: 260 start-page: 2279 year: 2013 ident: 9373_CR19 publication-title: J Neurol doi: 10.1007/s00415-013-6980-5 – volume: 24 start-page: 768 year: 2017 ident: 9373_CR25 publication-title: Eur J Neurol doi: 10.1111/ene.13285 – volume: 265 start-page: 159 year: 2018 ident: 9373_CR2 publication-title: J Neurol doi: 10.1007/s00415-017-8686-6 – volume: 13 start-page: 1 year: 2018 ident: 9373_CR44 publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-017-0741-y – volume: 26 start-page: 442 year: 2018 ident: 9373_CR50 publication-title: Eur J Neurol doi: 10.1111/ene.13835 – volume: 28 start-page: 965 year: 2018 ident: 9373_CR37 publication-title: Neuromuscul Disord doi: 10.1016/j.nmd.2018.08.002 – volume: 18 start-page: 25 year: 2018 ident: 9373_CR32 publication-title: BMC Urol doi: 10.1186/s12894-018-0332-9 – volume: 87 start-page: 5 year: 2016 ident: 9373_CR17 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2014-310164 – volume: 43 start-page: 1 year: 2016 ident: 9373_CR20 publication-title: Can J Neurol Sci doi: 10.1017/cjn.2016.37 – volume: 265 start-page: 2783 year: 2018 ident: 9373_CR46 publication-title: J Neurol doi: 10.1007/s00415-018-9065-7 – volume: 2 start-page: 1 year: 2010 ident: 9373_CR27 publication-title: J Radiat Onc Inform doi: 10.5166/jroi-2-1-6 – volume: 51 start-page: 884 year: 2015 ident: 9373_CR34 publication-title: Muscle Nerve doi: 10.1002/mus.24653 – volume: 104 start-page: 552 year: 2011 ident: 9373_CR38 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2011.09.012 – volume: 264 start-page: 621 year: 2017 ident: 9373_CR40 publication-title: J Neurol doi: 10.1007/s00415-016-8219-8 – year: 2018 ident: 9373_CR49 publication-title: Oncology doi: 10.1159/000492272 – volume: 15 start-page: 205 year: 2015 ident: 9373_CR21 publication-title: BMC Neurol doi: 10.1186/s12883-015-0412-3 – volume: 126 start-page: 175 year: 2016 ident: 9373_CR31 publication-title: J Neurooncol doi: 10.1007/s11060-015-1957-0 – volume: 262 start-page: 968 year: 2015 ident: 9373_CR8 publication-title: J Neurol doi: 10.1007/s00415-015-7664-0 – volume: 39 start-page: 253 year: 2016 ident: 9373_CR10 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-015-9889-6 – volume: 260 start-page: 951 year: 2013 ident: 9373_CR16 publication-title: J Neurol doi: 10.1007/s00415-012-6636-x – volume: 119 start-page: 1 year: 2019 ident: 9373_CR36 publication-title: Acta Neurol Belg doi: 10.1007/s13760-019-01097-4 – volume: 104 start-page: 273 year: 2014 ident: 9373_CR24 publication-title: S Afr Med J doi: 10.7196/SAMJ.7386 – volume: 261 start-page: 1684 year: 2014 ident: 9373_CR45 publication-title: J Neurol doi: 10.1007/s00415-014-7402-z – volume: 74 start-page: 166 year: 2016 ident: 9373_CR23 publication-title: Arq Neuropsiquiatr doi: 10.1590/0004-282X20150194 – volume: 104 start-page: 129 year: 2011 ident: 9373_CR18 publication-title: Mol Genet Metab doi: 10.1016/j.ymgme.2011.06.012 – volume: 35 start-page: 837 year: 2012 ident: 9373_CR43 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-012-9451-8 – volume: 15 start-page: e207 year: 2013 ident: 9373_CR29 publication-title: J Med Internet Res doi: 10.2196/jmir.2452 |
| SSID | ssj0008459 |
| Score | 2.334677 |
| SecondaryResourceType | review_article |
| Snippet | Pompe disease is a rare autosomal-recessive disorder characterised by limb-girdle myopathy and respiratory weakness in the late-onset form (LOPD). Various... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2010 |
| SubjectTerms | Age of Onset Cost of Illness Decision Trees Diagnosis Discordance Enzyme Replacement Therapy - methods Enzyme Replacement Therapy - trends Enzymes Glycogen Glycogen Storage Disease Type II - diagnosis Glycogen Storage Disease Type II - epidemiology Glycogen Storage Disease Type II - therapy Hereditary diseases Humans Medicine Medicine & Public Health Myopathy Neurology Neuroradiology Neurosciences Original Communication Practice Guidelines as Topic - standards Respiratory function Treatment Outcome α-Glucosidase |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS9xAFB6KluKLtvW2ui1T8M0OZDMzyeRRpOKLsrQqvoXMTRbcZNmsPvsj_AH-Nn-J5ySTiNgK9jHMmZNhci5fODdC9gADZEqPPIu5ThhYSc-Ukp5FhSik5AZ8XDtsIj09VZeX2TgUhdVdtnsXkmwsdV_shq2hMNEMU3x4yhkY3mVwdwrV8fefi97-KtGMSIu4iJjkUoRSmb_zeOmOXmHMV_HRxu0crf3fgT-T1QAz6UErF1_IB1d-JZ9OQiB9nTwc9vMHaeUpmD1wPnQ2ua0AjONjNZ26MG-ppgBsKQBFatu8vElNi9LSPkcdOVwDZmWYmb2gY4TiNER-KCbWX3U74TS0rKyrH-_ukeFLUt2UVNAaxMZtkPOjX2eHxywMa2AGENWCYcGc5SaLvEgUVz6xxsHvSmRTAITRqJBW8thmwiU4AzDlzgL2dGZkioJHymd8kyyVVem2CTVKp86KzAofC515nfBEag9ASyutjR2QUffNchM6meNAjeu878HcXH0OV583V5_HA7Lf75m1fTzepB52opAHna5zQFJJhh33YPlHvwzaiCGWonTVDdLwGECbitMB2WpFqH8dB6QFyiAH5GcnL8_M_32WnfeR75KVuBE5zFEckqXF_MZ9Ix_N7WJSz783mvIE0-wOSw priority: 102 providerName: Springer Nature |
| Title | Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes—the Pompe disease burden scale |
| URI | https://link.springer.com/article/10.1007/s00415-019-09373-2 https://www.ncbi.nlm.nih.gov/pubmed/31104135 https://www.proquest.com/docview/2226910672 https://www.proquest.com/docview/2232071827 |
| Volume | 266 |
| WOSCitedRecordID | wos000476506500021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: Springer LINK customDbUrl: eissn: 1432-1459 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0008459 issn: 0340-5354 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEB6aTSm9pP-N2zSo0Fsr6rVkWz6VNiT00mVJf9ibsf7KQmJv4k3OeYg8QJ6tT9IZW3YIobn0YhCWZMGMZj5rRvMBvEMMUCg99TwROuNoJT1XKvU8rmSVpsKgj-vJJvLZTC0WxTwcuLUhrXKwiZ2hto2hM_KP6MeyguqdJZ9WJ5xYoyi6Gig0NmCTKpXJCWx-2Z_ND0dbrGRHlxYLGfNUpDJcm-kuz1GpKUpco5QhkQue3HRNt_DmrVhp54IOHv3v4h_DVgCf7HOvLU_gnqufwoNvIbz-DK72RlZC1niGxhBdElstzxuE6NRsjo9dYGFqGcJdhvCR2T5bb9myqrZszFynGY4QyXLK116zOQF0FuJBjNLtfw8jcTWsbqxr_1xc0oQ3u-ruogVrUZncc_h5sP9j7ysPFA7cIM5ac7pGZ4UpYi8zJZTPrHH4ExPbHGFiPK1Sm4rEFtJlxAyYC2cRkTozNVUlYuUL8QImdVO7bWBG6dxZWVjpE6kLrzORpdoj_NJKa2MjmA7SK02ob040G0flWJm5k3iJEi87iZdJBO_HMau-usedvXcG6ZZhp7fltWgjeDu-xj1KgZeqds0Z9REJQjmV5BG87JVp_JxA_IVbJI3gw6Bd15P_ey2v7l7La3iYdJpNmYo7MFmfnrk3cN-cr5ft6S5s5Iu8e6rdsGOwdfj9119fWhx7 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LTtVAGP5D0Kgb70oVdUx0pRN6ZnqZLowxKIEAJywwObvauZmTQHugBwg7H4IH4Al8KJ_E_--NECI7Fi6bTqeT6Tff_03nvwC8Qw2QKT3yXEidcGRJz5WKPQ-LqIhjadDGtcUm0vFYTSbZzgL87mNhyK2y58SGqG1l6B_5CtqxJKN8Z-Lz7IBT1Sg6Xe1LaLSw2HSnJ7hlqz9tfMXv-16ItW-7q-u8qyrADZr-OafILitNFvooUVL5xBqHujq0KSqXcFTENpbCZpFLqFhdKp1FkeTMyBSFDJWn5EtI-beQx1NyIUsnwwYvVFFTnC2UUchjGUddkE4TqkeJrchNjhyUZCq5uGwIr6jbKyezjcFbe_C_TdVDuN9Ja_alXQuPYMGVj-HOduc88ATOV4eai6zyDKkeDS6bTY8r3IDQZbW_77oaUzVDMc9QHDPb-iJOa1aUlg1--dTDHup0Tt7oc7ZD2w_WnXYxCib42T-Jo2FlZV3959cZdXi5qW7CSFiNS8U9he83Mj_PYLGsSrcEzCidOhtlNvIi0pnXiUxi7VFcaqW1sQGMerTkpsveTkVE9vIh73SDsBwRljcIy0UAH4ZnZm3ukmtbL_doyjseq_MLKAXwdriNDETHSkXpqiNqIwUKVSXSAJ634B1eJ1FdIgHEAXzs0XzR-b_H8uL6sbyBu-u721v51sZ48yXcE82qIp_MZVicHx65V3DbHM-n9eHrZn0y-HHTKP8LzXlykw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB5VW1Rx4Z8SKGAkOIHVrJ0f54AQtF1RFVYrBFJvIfEPWqlNlmZbxI2H4AF4Dh6HJ2EmcVJVFb31wDGK41jO55nP8cx8AE-RA2SqHDsuZJlwtJKOKxU7HhZREcdSo4_rxCbS6VTt72ezFfjd58JQWGVvE1tDbWpN_8g30Y8lGdU7E5vOh0XMtievFl85KUjRSWsvp9FBZM9-_4bbt-bl7jZ-62dCTHY-br3lXmGAa6QBS05ZXkbqLHRRoqRyidEWOXZoUmQx4biITSyFySKbkHBdKq1BwmT1WBeFDJWjQkxo_ldTJBnxCFbf7ExnHwY_oKJWqi2UUchjGUc-ZadN3KMyVxQ0R-FKMpVcnHWL57juuXPa1v1Nrv_PE3cDrnnSzV53q-QmrNjqFqy992EFt-HX1qDGyGrH0AmgK2aL-UmNWxO6rA8PrVefahjSfIa0mZkuSnHesKIybIjYpx4OkMFzilNfshltTJg_B2OUZvClfxJHw6ra2ObPj5_U4dmmZZtgwhpcRPYOfLqU-bkLo6qu7D1gWpWpNVFmIieiMnNlIpO4dEg7S1WW2gQw7pGTa1_XneRFDvKhInWLthzRlrdoy0UAz4dnFl1Vkwtbb_TIyr2Fa_JTWAXwZLiNtokOnIrK1sfURgqksEqkAax3QB5eJ5F3ommIA3jRI_u083-P5f7FY3kMawju_N3udO8BXBXtAqNgzQ0YLY-O7UO4ok-W8-bokV-sDD5fNsz_Ar4afLM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+recent+pivotal+recommendations+for+the+diagnosis+and+treatment+of+late-onset+Pompe+disease+using+diagnostic+nodes-the+Pompe+disease+burden+scale&rft.jtitle=Journal+of+neurology&rft.au=Hundsberger%2C+Thomas&rft.au=Schoser%2C+Benedikt&rft.au=Leupold%2C+Daniela&rft.au=R%C3%B6sler%2C+Kai+Michael&rft.date=2019-08-01&rft.issn=1432-1459&rft.eissn=1432-1459&rft.volume=266&rft.issue=8&rft.spage=2010&rft_id=info:doi/10.1007%2Fs00415-019-09373-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-5354&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-5354&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-5354&client=summon |